Intelligence · Clinical Pipeline
Bristol-Myers Squibb Australia Pipeline
All ClinicalTrials.gov programs at Bristol-Myers Squibb Australia — phase, modality, and trial IDs.
- Programs
- 10
Quick answer
Bristol-Myers Squibb Australia has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
Bristol-Myers Squibb Australia Pty Ltd
Neuropsychiatric indications and potentially other conditions
1 trial -
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumors
1 trial -
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors
Bristol-Myers Squibb Australia Pty Ltd
Advanced Malignant Tumors
1 trial -
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb Australia Pty Ltd
Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)
1 trial -
A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases
Bristol-Myers Squibb Australia Pty Ltd
Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus
1 trial -
A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC
Bristol-Myers Squibb Australia Pty Ltd
Advanced Clear Cell Renal Cell Carcinoma
1 trial -
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Bristol-Myers Squibb Australia Pty Ltd
Acute Myeloid Leukemia and Myelodysplastic Syndrome
1 trial -
Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
Bristol-Myers Squibb Australia Pty Ltd
Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
1 trial -
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb Australia Pty Ltd
Non-small Cell Lung Cancer (NSCLC)
1 trial -
[14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Bristol-Myers Squibb Australia Pty Ltd
Advanced Solid Tumors
1 trial
Frequently asked questions
How many pipeline programs does Bristol-Myers Squibb Australia have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs